OBJECT: The authors conducted a phase I study of late infantile neuronal ceroid lipofuscinosis using an adenoassociated virus serotype 2 (AAV2) vector containing the deficient CLN2 gene (AAV2(CU)hCLN2). The operative technique, radiographic changes, and surgical complications are presented. METHODS: Ten patients with late infantile neuronal ceroid lipofuscinosis disease each underwent infusion of AAV2(CU)hCLN2 (3 x 10(12) particle units) into 12 distinct cerebral locations (2 depths/bur hole, 75 minutes/infusion, and 2 microl/minute). Innovative surgical techniques were developed to overcome several obstacles for which little or no established techniques were available. Successful infusion relied on preoperative stereotactic planning to optimize a parenchymal target and diffuse administration. Six entry sites, each having 2 depths of injections, were used to reduce operative time and enhance distribution. A low-profile rigid fixation system with 6 integrated holding arms was utilized to perform simultaneous infusions within a practical time frame. Dural sealant with generous irrigation was used to avoid CSF egress with possible subdural hemorrhage or altered stereotactic registration. RESULTS: Radiographically demonstrated changes were seen in 39 (65%) of 60 injection sites, confirming localization and infusion. There were no radiographically or clinically defined complications. CONCLUSIONS: The neurosurgical considerations and results of this study are presented to offer guidance and a basis for the design of future gene therapy or other clinical trials in children that utilize direct therapeutic delivery.
OBJECT: The authors conducted a phase I study of late infantile neuronal ceroid lipofuscinosis using an adenoassociated virus serotype 2 (AAV2) vector containing the deficient CLN2 gene (AAV2(CU)hCLN2). The operative technique, radiographic changes, and surgical complications are presented. METHODS: Ten patients with late infantile neuronal ceroid lipofuscinosis disease each underwent infusion of AAV2(CU)hCLN2 (3 x 10(12) particle units) into 12 distinct cerebral locations (2 depths/bur hole, 75 minutes/infusion, and 2 microl/minute). Innovative surgical techniques were developed to overcome several obstacles for which little or no established techniques were available. Successful infusion relied on preoperative stereotactic planning to optimize a parenchymal target and diffuse administration. Six entry sites, each having 2 depths of injections, were used to reduce operative time and enhance distribution. A low-profile rigid fixation system with 6 integrated holding arms was utilized to perform simultaneous infusions within a practical time frame. Dural sealant with generous irrigation was used to avoid CSF egress with possible subdural hemorrhage or altered stereotactic registration. RESULTS: Radiographically demonstrated changes were seen in 39 (65%) of 60 injection sites, confirming localization and infusion. There were no radiographically or clinically defined complications. CONCLUSIONS: The neurosurgical considerations and results of this study are presented to offer guidance and a basis for the design of future gene therapy or other clinical trials in children that utilize direct therapeutic delivery.
Authors: Ronald G Crystal; Dolan Sondhi; Neil R Hackett; Stephen M Kaminsky; Stefan Worgall; Philip Stieg; Mark Souweidane; Syed Hosain; Linda Heier; Douglas Ballon; Miles Dinner; Krystyna Wisniewski; Michael Kaplitt; Bruce M Greenwald; Joy D Howell; Kristin Strybing; Jonathan Dyke; Henning Voss Journal: Hum Gene Ther Date: 2004-11 Impact factor: 5.695
Authors: Y Mardor; Y Roth; Z Lidar; T Jonas; R Pfeffer; S E Maier; M Faibel; D Nass; M Hadani; A Orenstein; J S Cohen; Z Ram Journal: Cancer Res Date: 2001-07-01 Impact factor: 12.701
Authors: Mark H Tuszynski; Leon Thal; Mary Pay; David P Salmon; Hoi Sang U; Roy Bakay; Piyush Patel; Armin Blesch; H Lee Vahlsing; Gilbert Ho; Gang Tong; Steven G Potkin; James Fallon; Lawrence Hansen; Elliott J Mufson; Jeffrey H Kordower; Christine Gall; James Conner Journal: Nat Med Date: 2005-04-24 Impact factor: 53.440
Authors: Christopher Janson; Scott McPhee; Larissa Bilaniuk; John Haselgrove; Mark Testaiuti; Andrew Freese; Dah-Jyuu Wang; David Shera; Peter Hurh; Joan Rupin; Elizabeth Saslow; Olga Goldfarb; Michael Goldberg; Ghassem Larijani; William Sharrar; Larisa Liouterman; Angelique Camp; Edwin Kolodny; Jude Samulski; Paola Leone Journal: Hum Gene Ther Date: 2002-07-20 Impact factor: 5.695
Authors: Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi Journal: J Neurosci Res Date: 2016-11 Impact factor: 4.164
Authors: Jonathan B Rosenberg; Michael G Kaplitt; Bishnu P De; Alvin Chen; Thomas Flagiello; Christiana Salami; Eduard Pey; Lingzhi Zhao; Rodolfo J Ricart Arbona; Sebastien Monette; Jonathan P Dyke; Douglas J Ballon; Stephen M Kaminsky; Dolan Sondhi; Gregory A Petsko; Steven M Paul; Ronald G Crystal Journal: Hum Gene Ther Clin Dev Date: 2018-03-13 Impact factor: 5.032
Authors: Jonathan B Rosenberg; Dolan Sondhi; David G Rubin; Sébastien Monette; Alvin Chen; Sara Cram; Bishnu P De; Stephen M Kaminsky; Caroline Sevin; Patrick Aubourg; Ronald G Crystal Journal: Hum Gene Ther Clin Dev Date: 2014-08-21 Impact factor: 5.032
Authors: Jie Bu; Karen M Ashe; John Bringas; John Marshall; James C Dodge; Mario A Cabrera-Salazar; John Forsayeth; Edward H Schuchman; Krystof S Bankiewicz; Seng H Cheng; Lamya S Shihabuddin; Marco A Passini Journal: Mol Ther Date: 2012-07-24 Impact factor: 11.454